MICHAEL VOLK to Liver Neoplasms
This is a "connection" page, showing publications MICHAEL VOLK has written about Liver Neoplasms.
Connection Strength
2.951
-
Positron Emission Tomography Scan in Detecting and Locating Extrahepatic Recurrent Hepatocellular Carcinoma Post Orthotic Liver Transplant. Prog Transplant. 2020 12; 30(4):396-397.
Score: 0.320
-
Ruptured Hepatocellular Carcinoma following Transarterial Radioembolization. J Vasc Interv Radiol. 2018 09; 29(9):1302-1305.
Score: 0.278
-
Improving screening for hepatocellular carcinoma by incorporating data on levels of a-fetoprotein, over time. Clin Gastroenterol Hepatol. 2013 Apr; 11(4):437-40.
Score: 0.187
-
Quality improvement measures lead to higher surveillance rates for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci. 2013 Apr; 58(4):1157-60.
Score: 0.186
-
Liver transplantation for hepatocellular carcinoma: who benefits and who is harmed? Gastroenterology. 2008 May; 134(5):1612-4.
Score: 0.136
-
A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant. 2008 Apr; 8(4):839-46.
Score: 0.134
-
Early detection of liver cancer: diagnosis and management. Curr Gastroenterol Rep. 2008 Feb; 10(1):60-6.
Score: 0.134
-
Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark. 2007; 3(2):79-87.
Score: 0.124
-
Who decides? Living donor liver transplantation for advanced hepatocellular carcinoma. Transplantation. 2006 Nov 15; 82(9):1136-9.
Score: 0.123
-
The liver frailty index is a predictor of healthcare utilization after liver transplantation in older adults. Clin Transplant. 2024 01; 38(1):e15219.
Score: 0.100
-
Proton beam radiotherapy versus transarterial chemoembolization for hepatocellular carcinoma: Results of a randomized clinical trial. Cancer. 2023 11 15; 129(22):3554-3563.
Score: 0.098
-
Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology. 2022 07; 76(1):251-274.
Score: 0.088
-
Using Evidence-Based Criteria to Decrease CT Utilization for Liver Imaging. Curr Probl Diagn Radiol. 2022 Jul-Aug; 51(4):419-422.
Score: 0.088
-
Frailty, mortality, and health care utilization after liver transplantation: From the Multicenter Functional Assessment in Liver Transplantation (FrAILT) Study. Hepatology. 2022 06; 75(6):1471-1479.
Score: 0.088
-
Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology. 2022 05; 75(5):1289-1299.
Score: 0.087
-
A 2020 update on liver transplant for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2020 Oct; 14(10):885-900.
Score: 0.079
-
Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019 11; 157(5):1253-1263.e2.
Score: 0.074
-
Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology. 2019 05; 156(6):1683-1692.e1.
Score: 0.071
-
Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma. Transplantation. 2017 05; 101(5):1001-1008.
Score: 0.063
-
Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):477-482.
Score: 0.058
-
Estimation of Liver Transplant Related Survival Benefit: the Devil Is in The Details. Gastroenterology. 2016 Feb; 150(2):534-5.
Score: 0.058
-
Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. J Hepatol. 2015 Mar; 62(3):617-24.
Score: 0.053
-
Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangiocarcinoma. Liver Transpl. 2014 Jan; 20(1):81-8.
Score: 0.050
-
A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. J Hepatol. 2014 Feb; 60(2):290-7.
Score: 0.050
-
Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 2012 May; 21(5):793-9.
Score: 0.044
-
Patient involvement in healthcare is associated with higher rates of surveillance for hepatocellular carcinoma. J Clin Gastroenterol. 2011 Sep; 45(8):727-32.
Score: 0.043
-
Estimation of the harm to the waiting list as a crucial factor in the selection of patients with hepatocellular carcinoma for liver transplantation. Transplant Proc. 2010 May; 42(4):1194-6.
Score: 0.039
-
The survival benefit of liver transplantation in hepatocellular carcinoma patients. Dig Liver Dis. 2010 Sep; 42(9):642-9.
Score: 0.039
-
Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009 Jul; 30(1):37-47.
Score: 0.036
-
Applying reinforcement learning techniques to detect hepatocellular carcinoma under limited screening capacity. Health Care Manag Sci. 2015 Sep; 18(3):363-75.
Score: 0.013
-
A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010 Mar; 8(3):280-8, 288.e1.
Score: 0.009